Global capabilities

In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., speaks with operations administrator Mark Brown to discuss the significance of collaborating with administrators.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to honor Black History Month. They reflect on important advancements in healthcare and laboratory medicine that were led by Black healthcare professionals and scholars. They also discuss health inequities that impact communities throughout the United States.

This week's research roundup feature: Both targeted therapies and immunotherapies provide benefit in resected Stage III melanoma. We hypothesized that the combination of targeted and immunotherapy given prior to therapeutic lymph node dissection (TLND) would be tolerable and drive robust pathologic responses. 

In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, speaks with outreach solutions strategists Ellen Dijkman Dulkes and Brianne Newton. They discuss how an outreach program can work with its customers on process improvements by using periodic visits and data-driven discussions.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Stefan Grebe, M.D., Ph.D., co-director of the Clinical Mass Spectrometry and Test Development Laboratory in the Department of Laboratory Medicine and Pathology, and Irina Bancos, M.D., consultant in the Division of Endocrinology, Diabetes, and Metabolism with a joint appointment in biochemistry and immunology. They discuss the diagnosis and management of adrenal gland tumors.

Recognizing the powerful role genes can play in diagnosing illness and guiding treatment, the Division of Laboratory Genetics and Genomics at Mayo Clinic spearheaded a testing expansion, implementing and upgrading more than 60 advanced sequencing and biochemical assays in 2023 and planning for even more this year.

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' test panel provides comprehensive evaluation of patients with suspected monogenic early onset inflammatory bowel disease, or IBD. Accurate diagnosis is key to guiding therapy for patients, who might be as young as 2 years of age.

This week's research roundup feature: Patients with dementia with Lewy bodies (DLB) may have Alzheimers disease (AD) pathology that can be detected by plasma biomarkers. Our objective was to evaluate plasma biomarkers of AD and their association with positron emission tomography (PET) biomarkers of amyloid and tau deposition in the continuum of DLB, starting from prodromal stages of the disease.

Depending on the types of specimens that are referred to the outreach laboratory, there may be an opportunity to share a customer performance update report with the client so that they can align with, or even develop their own laboratory continuous improvement initiatives. This data-sharing provides valuable metrics and allows the client an opportunity to improve their services. Through identifying issues and working together to resolve them, the customer and the laboratory are aligned in their mission of putting the needs of the patient first.

In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., speaks with Alfredo Quinones-Hinjosa, M.D., a neurosurgeon and scientist at Mayo Clinic. From humble beginnings as a migrant worker, his story is one of resilience, determination, and a relentless pursuit of knowledge.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss current activity of infectious diseases.

PACE/State of FLPresentation Recording Coming Soon Sudden cardiac death (SCD) is a devastating event that occurs unexpectedly, often without any prior symptoms. This webinar will discuss how postmortem genetic testing may be used in conjunction with a traditional autopsy to assist with establishing cause and manner of death.